Innovation for the Future of Drug Discovery

At SEEDSUPPLY, we are committed to transforming the landscape of drug discovery.
Leveraging our proprietary technologies, including an advanced Affinity Selection Mass Spectrometry, we enable the direct identification of hit compounds and drug target proteins, even for challenging membrane proteins such as SLC transporters and GPCRs.
Our unique approach focuses on what truly matters: finding novel first-in-class therapeutics by accessing targets and ligands that conventional methods often overlook.
Through our comprehensive screening of 400,000 compounds and 17,000 proteins under native conditions, we accelerate breakthroughs that open new therapeutic possibilities.
SEEDSUPPLY empowers researchers and pharmaceutical innovators worldwide, bridging the gap between untapped biological insights and real-world therapeutics.

Revolutionizing Drug Discovery: A New Process Proposal from SEEDSUPPLY

Traditional drug discovery begins with extensive research to identify and validate target molecules, followed by screening campaigns to find suitable compounds. Only after these steps does lead generation and optimization begin. This process, while proven, is often time-consuming and resource-intensive.
At SEEDSUPPLY, we propose an innovative, accelerated approach:
By leveraging a pre-prepared database of binding compounds or conducting rapid preliminary screenings (BST: Binding Selection Technology), we first obtain compounds that already interact with potential targets.
Using these compounds, we simultaneously advance target research and target determination.
This enables a seamless and swift transition to lead generation.
Our modified process shortens timelines, reduces risks, and maximizes opportunities for discovering first-in-class therapies.
With SEEDSUPPLY, drug discovery no longer waits — it moves forward from the very start.

News

73rd ASMS Conference on Mass Spectrometry and Allied Topics in Baltimore

We will be presenting two posters and exhibiting at the 73rd American Society for Mass Spectrometry (ASMS) Conference,
which will be held from June 1–5 in Baltimore.
The titles of our poster presentations are as follows:
1. Ligand Identification for Orphan GPCRs Using Affinity Selection Mass Spectrometry
2. Target Identification Using Affinity Selection Mass Spectrometry and a Protein Library of 17,000 Proteins, Including Membrane Proteins

New service: compound submissions for our binding protein screening service

April 21, 2025
We are now accepting compound submissions for our binding protein screening service.
2025年4月21日
結合タンパク質スクリーニングの化合物受付を開始しました。